title: [Expression of cellular FLICE inhibitory protein (cFLIP) in endometrial adenocarcinoma].
abstract: OBJECTIVE
  Cellular FLICE inhibitory protein (cFLIP) is a new-found member of the inhibitors of apoptosis. It has been reported to be overexpressed in various human cancers. We investigated the expression of cFLIP in endometrial adenocarcinoma and its association with clinicopathological features and proliferating cell nuclear antigen-labeling index (PCNA-LI).
  
  
  METHODS
  cFLIP and PCNA-LI were determined in endometrial tissue samples including 42 endometrial adenocarcinoma tissues, 20 normal proliferative endometrial tissues, and 40 hyperplastic tissues with (n=10) or without (n=30) atypia by immunohistochemistry.
  
  
  RESULTS
  The positive rates of cFLIP expression in normal proliferative samples of endometrium, hyperplastic samples, and endometrial adenocarcinomas were (55.0+/-11.4)%, (72.5+/-7.1)%, and (83.3+/-5.8)%, respectively. Scoring on the basis of the percentage of positive cells and the intensity of positive immunostaining indicated that the expression level of cFLIP was significantly higher in adenocarcinoma than in normal proliferative endometrium (P< 0.01) and hyperplastic endometrium with or without atypia (P< 0.05);but no significant difference was found between the later two groups. PCNA-LI were (12.01+/-2.07)%,(20.26+/-6.99)%, (27.10+/-3.01)%, and (41.65+/-10.16)%, respectively in the adenocarcinoma groups with different cFLIP levels showed as -, +, ++, +++. Statistical analysis showed that cFLIP expression was significantly associated with PCNA-LI (r=0.7471,P< 0.01). In addition, cFLIP expression was also significantly associated with clinical stage (P< 0.05), the presence of invasion to >1/2 myometrium (P< 0.05) and positive lymph node metastasis (P< 0.01) of endometrial adenocarcinomas.
  
  
  CONCLUSIONS
  Overexpression of cFLIP is tumor specific, which may be a late event in the tumor development of endometrial adenocarcinoma.
authors.affiliation: Department of Gynecology and Obstetrics, Renmin Hospital, Wuhan University, Wuhan, Hubei, 430060, PR China. zhouxd7710@sina.com.cn
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Chen
authors.forename: Yuan-Jiao
authors.initials: YJ
authors.lastname: Liu
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Ze-Sheng
authors.initials: ZS
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D002352:Carrier Proteins / Q000032:analysis*; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D004717:Endometrium / Q000737:chemistry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis
chemical_list: D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; C506386:CFLAR protein, human; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D018809:Proliferating Cell Nuclear Antigen